Centre for pharma and biotechnology                                                                                                                                                                         Advertisement

Indeed, dislike he's curing disease." It's a without any preparation remark that is tossed around when individuals consider their occupations excessively important. However, imagine a scenario where you truly could cure growth or different illnesses. On the other hand concoct new advances that could expand crop yields by 20 or 25 percent? That may be a justifiable reason motivation to consider your occupation important. Working with plant-and concoction based mixes, pharmaceutical organizations work their magic to make meds that cure a few ailments, oversee others, and shield us from contamination in any case. Huge Pharma incorporates a modest bunch of significant organizations that overwhelm the business. While a considerable lot of these organizations likewise create creature wellbeing items, animals sustain supplements, vitamins, and a large group of different merchandise, this profile will concentrate exclusively on their medication items used to treat human disease. Enormous Pharma is one of the world's most gainful ventures. Amid the most recent 30 years, the industry has burned through billions of dollars on examination and procured billions consequently. In 2006 alone, the pharmaceutical business presented 31 noteworthy medications and sold $643 billion in items around the world a 7 percent expansion more than 2005 deals, as per the medication statistical surveying firm IMS Health. U.S. deals beat the national normal with development of 8.3 percent (up from 5.4 percent development in 2005). Contingent upon their size and methodology, pharma organizations may lead broad examination in-house or they may try to permit promising medications from the scholarly world, other pharma firms, or biotechnology organizations. The last firms are for the most part littler than their Big Pharma rivals, and they utilize cell and biomolecular procedures to make solutions or analyze ailment.Biotechnology, a fresher territory, has then again been the sweetheart and the worst thing about financial specialists as of late. Basically, biotechnology, the connected learning of science, tries to copy or change the capacity of a living cell so it will work in a more unsurprising and controllable way. The biotechnology business utilizes progresses as a part of hereditary qualities examination to create items for human infections and conditions. A few biotech organizations likewise utilize hereditary innovation to different closures, similar to the control of products. Biotech open doors generally reflect those in the pharmaceutical business. The key distinction is that biotech firms are a great deal more centered around examination since they are as yet building up their underlying items. Biotech firms have a tendency to extend their advertising and deals strengths when-and if-a feasible item nears FDA endorsement. Furthermore, it's ended up regular for little organizations to look for unions with bigger organizations that as of now have the imperative framework set up for these capacities. This implies occupations for nonscientists are scarcer in biotech than in pharmaceuticals. Biotech and pharma have been performing exceedingly well in respect to different enterprises as of late. Keeping in mind there are issues sneaking in the shadows at a few organizations, by and large the future searches brilliant for these businesses. In spite of the fact that there is a lot of open debate (e.g., the good and moral inquiries encompassing genomics and the valuing and patent practices of Big Pharma), interest for medications is developing, powered by a maturing populace and blooming global markets. Despite whether you work for Big Pharma or little biotech, don't get excessively appended, making it impossible to the norm. Nowadays, the business environment can change overnight. One need just take a gander at late biotech stock instability for adequate confirmation of that. Also, as one insider says, "Even in Big Pharma, if there's a merger or a twist off, you can undoubtedly wind up without an occupation."


Evaluating -Insiders say this might be the greatest issue the business right now confronts. Who will pay the expense of medication improvement? As more medicines get to be accessible, will just the rich have entry to them?Physician recommended drug costs are rising every year, while back up plans are getting progressively more stringent about which prescriptions they'll repay their clients for. Energizing new medications can cost thousands or even a huge number of dollars per treatment. Giving value help to seniors has been an issue for quite a long while. Numerous support value controls to keep costs from soaring, a move the pharmaceutical business restricts.

Associations AND STRATEGIC ALLIANCES

A developing number of Big Pharma organizations are joining forces in medication advancement with development rich biotech firms, or purchasing the organizations out and out. In 2006, Big Pharma spent generally $17 billion for more than 250 biotech bargains, up from 150 in 2003, as per funding firm Burrill and Company. Besides, Big Pharma is progressively looking to biotech to help it discover potential treatments for fizzled clinical aggravates, a strategy called "repositioning." Pfizer's blockbuster Viagra is one case of finding another utilization for an apparent disappointment: The surely understood treatment for erectile brokenness started its gone through the pipeline as an exploratory heart solution. As of late, Pfizer, Roche, and Eli Lilly all marked manages the minor biotech firm Gene Logic to research their fizzled clinical competitors in the trust of making their R&D programs more gainful. Biotech organizations, particularly those managing agribusiness, are additionally adjusting to colleges to boost their exploration abilities. A few colleges, similar to the University of Rochester in New York, are creating focuses and hatcheries that will give youngster biotech organizations the assets they have to develop. THE RISE OF GENERICS,-At the point when a medication goes "off patent," other medication organizations are allowed to offer nonexclusive forms, synthetically indistinguishable duplicates that regularly cost significantly less than the trademarked rendition. The licenses on some of Big Pharma's most productive medications have lapsed in the previous couple of years. Illustrations incorporate Merck's Zocor, a cholesterol-bringing down medication; Pfizer's onetime blockbuster Zoloft, used to mitigate discouragement; and Bristol-Myers Squibb's cholesterol reducer Pravachol. These medications were focused in 2006 by Teva, the Israel-based nonexclusive pharmaceuticals producer.Yet, as non specific medication makers have turned out to be more forceful in their deals and showcasing endeavors, makers of marked pharmaceuticals have turned out to be more fiery in guarding their turf. Some Big Pharma organizations have procured bland medication makers, for example, Novartis' securing of Eon and Hexal. Those augmentations, and the company's obtaining of biotech firm Chiron, are a piece of Novartis' system of turning into a "one-stop shop" for its biggest medication clients: governments and oversaw care associations. Antibodies-Immunizations long held a low spot on the medication advancement command hierarchy as Big Pharma sought after items that customarily offered a superior degree of profitability. (Part of the explanation behind this is creating countries that need immunizations the frequently do not have the assets to pay for them.) The circumstance has changed, be that as it may, because of a recharged drive to deliver antibodies that will avoid or treat crushing sicknesses regular in the created world, for example, growth and Alzheimer's malady. A few specialists are anticipating that antibodies will in the long run supplant different solutions to wind up Big Pharma's greatest dealers.Today, there are around 450 immunizations being developed tending to such wellbeing dangers as hepatitis, HIV, and bosom growth. Drug firms are charging more for recently created antibodies than they could for more established ones, a circumstance that is impelling immunization R&D. Be that as it may, government/industry organizations are enhancing the immunization improvement picture, as well. The Group of Seven industrialized countries declared its dedication in mid 2007 to give $1.5 billion in a supposed "development market responsibility" to finance building up nations' buy of pneumococcal immunizations. The trust is that this activity will give a motivator to pharma organizations to create and make new immunizations to battle irresistible maladies. Huge PHARMA-The greater part of Big Pharma organizations are headquartered in the United States, yet a few are situated in western Europe-particularly the United Kingdom, Switzerland, Germany, and France. Most pharma organizations headquartered in the United States are found east of the Mississippi, with the best fixation in New Jersey. Huge Pharma organizations come in two styles: broadened and nondiversified. Differentiated organizations, which incorporate Johnson and Johnson, Abbott Laboratories, and Wyeth, keep up other medicinal services related organizations, for example, shopper wellbeing item divisions and therapeutic gadget organizations, while those that are nondiversified-Eli Lilly, Merck-concentrate exclusively on the advancement and offer of medications. Lately, however, broadened organizations have been stripping their nonpharma worries for the leaner and more productive medication business. Bristol-Myers Squibb, for case, sold Clairol, the main hair-items organization in the United States, to Procter and Gamble in 2001. BIOTECH -In spite of the accomplishment of such biotech mammoths as Amgen and Genentech, a substantial greater part of biotech shops are still sufficiently little for everybody to know others' name. Yet, a developing number is joining the world class gathering of biotech firms that have FDA-affirmed drugs available; somewhere around 2000 and 2003, the FDA endorsed nearly 132 new medications and immunizations and new signs for existing items. Once a biotech organization has achieved the phase at which it has an item coming to market, its employments extend from the essentially science-centered to incorporate promoting, assembling, building, and deals. Socially, organizations have a tendency to have developing agonies as they move from R&D to commercialization, yet their associations have a tendency to stay much leaner and compliment than those in Big Pharma. Despite the fact that there are 1,466 biotech firms in the United States (318 of them traded on an open market), with exactly 200,000 aggregate representatives, the biotech business is altogether littler than the pharma business. Still, this is a dynamic segment. Somewhere around 1992 and 2002, income for the indus

Drugs.com - Daily MedNews

Can HIV Drugs Boost Syphilis Risk?

MONDAY, Jan. 16, 2017 -- Gay and bisexual men taking antiretroviral drugs to treat HIV infection may be at increased risk for syphilis, new research contends. Based on a review of available evidence, the investigators concluded that the drugs may... Posted: Mon 16th of January, 2017

James Bond Has Kicked Butts, But His Co-Stars Haven't

MONDAY, Jan. 16, 2017 -- Being a secret agent is risky enough without adding cigarette smoking to the mix. So it's good news that James Bond seems to have kicked the health-harming habit about 15 years ago, a new study says. Still, since 1962,... Posted: Mon 16th of January, 2017

For a Colicky Baby, You Might Give Acupuncture a Try

MONDAY, Jan. 16, 2017 -- For beleaguered parents desperate to soothe a colicky baby, Swedish researchers have a novel suggestion -- acupuncture. After two weeks of treatment, about two-thirds of babies given acupuncture no longer had colic compared... Posted: Mon 16th of January, 2017

Medical Groups Raise Blood Pressure Rx Threshold for Healthy Adults Over 60

MONDAY, Jan. 16, 2017 -- Two leading medical organizations are recommending a less aggressive target for the treatment of high blood pressure in adults 60 and older who are otherwise healthy. Traditionally, the threshold for high blood pressure has... Posted: Mon 16th of January, 2017

First Stop for Scuba Divers: The Dentist's Office?

MONDAY, Jan. 16, 2017 -- The first time she tried scuba diving, Vinisha Ranna felt a squeezing sensation in her teeth. That experience led to a study that concluded divers often encounter dental problems underwater. Potentially, these problems... Posted: Mon 16th of January, 2017

'Superbug' May Be More Widespread Than Thought

MONDAY, Jan. 16, 2017 -- A type of potentially deadly drug-resistant bacteria is more widespread in U.S. hospitals than previously thought and needs to be more closely monitored, a new study suggests. Researchers checked for cases of illness caused... Posted: Mon 16th of January, 2017

Debunking Winter Weather Myths

MONDAY, Jan. 16, 2017 -- A hot toddy may seem like a good way to stay toasty on a freezing day because it makes blood rush to your skin's surface. But drinking alcohol actually speeds heat loss, according to experts. That's just one common myth... Posted: Mon 16th of January, 2017

Most Smokers With Mental Illness Want to Kick the Habit

MONDAY, Jan. 16, 2017 -- Nearly six in 10 Americans with severe mental illness smoke, and a new study suggests that many of them want to quit. The problem is that many of these patients don't get help from their psychiatrists and caseworkers,... Posted: Mon 16th of January, 2017

Can Coffee Perk Up Heart Health, Too?

MONDAY, Jan. 16, 2017 -- The caffeine in your morning cup of joe may do more than jolt you awake -- it may also help dampen the type of inflammation that's linked to heart disease risk factors, a new study suggests. Researchers found that an... Posted: Mon 16th of January, 2017

IRS Reminds Millions About Fines for Not Signing Up for Obamacare

MONDAY, Jan. 16, 2017 -- Even as Republicans in Congress race to repeal the Affordable Care Act, the IRS is reminding millions of Americans they still need to sign up soon for health insurance if they don't want to pay fines. The Internal Revenue... Posted: Mon 16th of January, 2017

Parents Have Mixed Views on When to Keep Sick Kids Out of School

MONDAY, Jan. 16, 2017 -- American parents don't always agree when to keep their children home sick from school, a new poll reveals. The poll included almost 1,500 parents nationwide. All had at least one child aged 6 to 18. The research found that... Posted: Mon 16th of January, 2017

Health Highlights: Jan. 16, 2017

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Study Examines Genital Injuries in U.S. Veterans Bomb blasts caused most of the genital or urinary tract wounds suffered by 1,367 men in the... Posted: Mon 16th of January, 2017

Kids Born to Opioid-Addicted Moms Seem to Fare Poorly in School

MONDAY, Jan. 16, 2017 -- Children exposed to addictive drugs in the womb may be more likely to perform poorly in school, Australian researchers report. In the study, these exposed kids lagged behind their peers on grade-level tests of reading,... Posted: Mon 16th of January, 2017

Health Tip: Ward Off Infections During Pregnancy

-- Infections can be a serious threat to pregnant women and their fetuses. To help ward off infections while you're pregnant, the American Academy of Pediatrics advises: Wash your hands frequently, particularly when you've been around children.... Posted: Mon 16th of January, 2017

Health Tip: Use Ice to Ease Ankle Sprain Pain

-- Ice can help ease the pain and swelling of a sprained ankle, but it's important to use the therapy properly. The American Academy of Family Physicians suggests: Never apply ice for longer than 20 minutes. Always remove ice if the area starts... Posted: Mon 16th of January, 2017

Taking the Bite Out of Frostbite

SUNDAY, Jan. 15, 2017 -- Did you know frostbite can occur within minutes? Keeping fingers and toes warm and dry when you work or play outside is a must in icy weather, the American Academy of Orthopaedic Surgeons (AAOS) says. Frostbite occurs when... Posted: Sun 15th of January, 2017

Pediatricians Offer Heads-Up for Preventing Soccer Injuries

SATURDAY, Jan. 14, 2017 -- As children's soccer has become more popular in the United States, soccer-related injuries have also become more common, the American Academy of Pediatrics (AAP) says. People can get hurt playing soccer if they collide... Posted: Sat 14th of January, 2017

House Joins Senate in Bid to Repeal Obamacare

FRIDAY, Jan. 13, 2017 -- The U.S. House of Representatives voted Friday afternoon to join the Senate in passing a measure to protect efforts to repeal the Affordable Care Act from a possible Senate filibuster. The Senate took the first step in the... Posted: Fri 13th of January, 2017

Head for the Hills With Sled Safety in Mind

FRIDAY, Jan. 13, 2017 -- When temperatures drop and snow falls, children are ready to reach for their hats, scarves -- and sleds. Sledding and snow tubing are among the fun winter activities that families can enjoy together. But, there are steps... Posted: Fri 13th of January, 2017

Many College Women Ignore Indoor Tanning's Risks

FRIDAY, Jan. 13, 2017 -- Despite the known dangers, many white female college students continue to tan indoors, a new study finds. Indoor tanning can lead to premature skin aging and skin cancers, including potentially deadly melanoma. It's... Posted: Fri 13th of January, 2017

Drugs.com - Pharma Industry News

Monthly News Roundup - December 2016

Biogen’s Spinraza Approved for Spinal Muscular Atrophy The U.S. Food and Drug Administration (FDA) has cleared Biogen's Spinraza (nusinersen), the first drug for spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting... Posted: Sat 31st of December, 2016

Monthly News Roundup - November 2016

Novo Nordisk’s Xultophy 100/3.6 FDA-Approved for Type 2 Diabetes This month the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Xultophy 100/3.6 (insulin degludec and liraglutide), a once-daily injection of insulin degludec... Posted: Wed 30th of November, 2016

Monthly News Roundup - October 2016

Merck’s Zinplava Approved to Fend Off Return of Clostridium Difficile Zinplava (bezlotoxumab) has been FDA-approved to reduce the recurrence of Clostridium difficile infection (CDI) in adults who are receiving antibacterial drug treatment for... Posted: Mon 31st of October, 2016

Monthly News Roundup - September 2016

Amjevita, a Biosimilar to Humira, Wins FDA Approval Amgen’s Amjevita (adalimumab-atto) is the first adalimumab (Humira) biosimilar approved by the U.S. Food and Drug Administration (FDA) and is used for the treatment of seven inflammatory... Posted: Thu 29th of September, 2016

Monthly News Roundup - August 2016

FDA Approves Erelzi: Sandoz’s Biosimilar For Enbrel A third U.S. biosimilar has been FDA-approved; this time it’s Erelzi (etanercept-szzs), a biosimilar to Amgen’s tumor necrosis factor (TNF) blocker Enbrel. Sandoz’s Erelzi is the first... Posted: Thu 1st of September, 2016

FDA Approves First Generic Version of Widely Used Influenza Drug Tamiflu

On August 3, 2016, the U.S. Food and Drug Administration approved the first generic version of Tamiflu (oseltamivir phosphate), a widely used medication for the treatment of the flu (influenza A and B) in patients two weeks of age and older who have... Posted: Fri 5th of August, 2016

Kratom Seized in California by US Marshals Service

August 4, 2016 -- The U.S. Food and Drug Administration announced today that the U.S. Marshals Service seized more than 100 cases of products labeled as containing kratom. The products are distributed by Nature Therapeutics LLC, which does business... Posted: Thu 4th of August, 2016

Monthly News Roundup - July 2016

Injectable Adlyxin FDA-Approved for Type 2 Diabetes The FDA has approved Sanofi’s Adlyxin (lixisenatide), a new once-daily injectable type 2 diabetes medication. Adlyxin is classified as an incretin mimetic/GLP-1 receptor agonist. For... Posted: Sun 31st of July, 2016

FDA Updates Warnings for Fluoroquinolone Antibiotics

July 26, 2016 -- The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and... Posted: Wed 27th of July, 2016

FDA approves first absorbable stent for coronary artery disease

July 5, 2016 -- The U.S. Food and Drug Administration today approved the first fully absorbable stent to treat coronary artery disease. The Absorb GT1 Bioresorbable Vascular Scaffold System (BVS), which releases the drug everolimus to limit the... Posted: Wed 6th of July, 2016

Monthly News Roundup - June 2016

Epclusa: First Approval For All Major Forms of Chronic Hepatitis C Virus The U.S. Food and Drug Administration (FDA) has given the go-ahead to Epclusa (sofosbuvir and velpatasvir), a nucleotide analog polymerase inhibitor and pan-genotypic NS5A... Posted: Thu 30th of June, 2016

FDA clears first test to detect specific genetic markers for certain antibiotic-resistant bacteria directly from clinical specimens

June 29, 2016 -- The U.S. Food and Drug Administration today cleared for marketing the Xpert Carba-R Assay, an infection control aid that tests patient specimens to detect specific genetic markers associated with bacteria that are resistant to... Posted: Wed 29th of June, 2016

FDA approves implantable device that changes the shape of the cornea to correct near vision

June 29, 2016 -- The U.S. Food and Drug Administration today approved the Raindrop Near Vision Inlay, a device implanted in the cornea (the clear, front surface) of one eye to improve near vision in certain patients with presbyopia. It is the second... Posted: Wed 29th of June, 2016

FDA targets unlawful internet sales of illegal prescription medicines during International Operation Pangea IX

June 9, 2016 -- The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, announced that it took action this week against 4,402 websites that illegally sell potentially dangerous, unapproved... Posted: Thu 9th of June, 2016

FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer

June 1, 2016 -- The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can... Posted: Wed 1st of June, 2016

Monthly News Roundup - May 2016

FDA Approves Zinbryta for Multiple Sclerosis Multiple sclerosis, a chronic, inflammatory, autoimmune disease of the central nervous system, has been reported as the leading cause of disability in young adults 20 to 40 years of age. The US Food... Posted: Wed 1st of June, 2016

FDA takes significant steps to protect Americans from dangers of tobacco through new regulation

May 5, 2016 -- Today, the U.S. Food and Drug Administration finalized a rule extending its authority to all tobacco products, including e-cigarettes, cigars, hookah tobacco and pipe tobacco, among others. This historic rule helps implement the... Posted: Fri 6th of May, 2016

FDA reminds health care professionals not to use drug products intended to be sterile from Medaus

May 5, 2016 -- The U.S. Food and Drug Administration is reminding health care professionals and patients not to use drugs intended to be sterile that were produced by Medaus Inc., due to lack of sterility assurance. The FDA has issued a formal... Posted: Fri 6th of May, 2016

FDA launches public education campaign to prevent and reduce tobacco use among LGBT young adults

May 2, 2016 -- The U.S. Food and Drug Administration today announced the launch of a historic public education campaign aimed at preventing and reducing tobacco use among lesbian, gay, bisexual and transgender (LGBT) young adults ages 18-24. Of the... Posted: Mon 2nd of May, 2016

Monthly News Roundup - April 2016

First-Time Generic Approved for Statin Crestor High cholesterol, high low-density lipoprotein (LDL) or “bad cholesterol”, and triglycerides increase the risk for serious heart disease and may lead to heart attacks and strokes. The FDA has now... Posted: Sat 30th of April, 2016

Drugs.com - Clinical Trials

Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo

MARLBOROUGH, Mass. January 14, 2017 --(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that results of a pivotal Phase 2/3 study (SEP360-202) evaluating novel drug candidate dasotraline in children ages 6 to 12 years with... Posted: Sat 14th of January, 2017

Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial

OSAKA, Japan and FLORHAM PARK, N.J., Jan. 12, 2017 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi") has announced that cefiderocol (S-649266), a novel siderophore cephalosporin in late-stage development, met the FDA pre-specified... Posted: Thu 12th of January, 2017

VivaGel BV granted QIDP and Fast Track designation by US FDA

Melbourne, Australia; 12 January 2017: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug... Posted: Thu 12th of January, 2017

Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with Keytruda (pembrolizumab)

WILMINGTON, D.E. & KENILWORTH, N.J. January 9, 2017 – Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program... Posted: Mon 9th of January, 2017

Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid

ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with elevated low... Posted: Sun 8th of January, 2017

Genprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex for Late Stage Non-Small Cell Lung Cancer

AUSTIN, TX, January 6, 2017 – Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase... Posted: Fri 6th of January, 2017

Neurelis Intranasal Diazepam Treatment For Epilepsy Granted Fast Track Designation By FDA

SAN DIEGO, Jan. 4, 2017 /PRNewswire/ -- Neurelis, Inc. today announced that the US Food and Drug Administration (FDA) has designated NRL-1 (intranasal diazepam) as a Fast Track Development program for the management of selected, refractory patients... Posted: Wed 4th of January, 2017

Senhwa Biosciences CX-4945 Granted Orphan Drug Designation by the US FDA in Cholangiocarcinoma

TAIPEI, Taiwan and SAN DIEGO, Jan. 4, 2017 /PRNewswire/ -- Senhwa Biosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CX-4945 for the treatment of cholangiocarcinoma. CX-4945... Posted: Wed 4th of January, 2017

NewVac Reports Primary Endpoint Met in Phase II Clinical Trial of Quisinostat in Combination with Paclitaxel and Carboplatin in Platinum-Resistant Ovarian Cancer

SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- NewVac LLC reported meeting all primary endpoints in the Phase II Clinical Trial of Quisinostat, novel selective oral histone deacetylase (HDAC1) inhibitor, which NewVac licensed from Janssen Pharmaceutica NV.... Posted: Tue 3rd of January, 2017

Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis

CARMIEL, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim results from the Company’s phase II clinical trial of alidornase alfa for the treatment of Cystic... Posted: Tue 3rd of January, 2017

Innocoll Receives Refusal to File Letter from U.S. FDA for XaraColl (bupivacaine HCl collagen-matrix implants) New Drug Application

ATHLONE, Ireland, Dec. 29, 2016 (GLOBE NEWSWIRE) -- Innocoll (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company, today announced that it has received a Refusal to File letter from the United States Food and Drug... Posted: Thu 29th of December, 2016

Anthera Announces the Phase 3 SOLUTION Study with Sollpura in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed

HAYWARD, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the top line results of the SOLUTION clinical study in cystic fibrosis patients with exocrine pancreatic insufficiency (EPI). The study... Posted: Tue 27th of December, 2016

Roche’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study

Basel, 22 December 2016 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with hemophilia A and inhibitors... Posted: Thu 22nd of December, 2016

Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis

LEXINGTON, Mass.-- December 21, 2016(BUSINESS WIRE) -- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a U.S.-based Phase 2 clinical trial evaluating CTP-656 (deuterated ivacaftor), a next generation CFTR potentiator... Posted: Wed 21st of December, 2016

Lexicon Reports Positive Top-Line Results in Second Pivotal Phase 3 Study for Sotagliflozin in Patients with Type 1 Diabetes

The Woodlands, Texas, December 21, 2016 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that its pivotal inTandem2 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in... Posted: Wed 21st of December, 2016

Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis Initiated and Open for Screening

BEVERLY, MA – Dec. 19, 2016 (GLOBE NEWSWIRE) Cellceutix Corporation, (OTCQB: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic... Posted: Tue 20th of December, 2016

Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions Due to Peanut Allergy

TOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas") and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., "Immunomic Therapeutics") today announced that the U.S. Food and... Posted: Tue 20th of December, 2016

Juno Therapeutics' and Celgene Corporation's Investigational Drug JCAR017 Granted Breakthrough Therapy Designation from FDA for Relapsed/Refractory Diffuse Large B-cell Lymphoma

SEATTLE & SUMMIT, N.J.--(BUSINESS WIRE) December 20, 2016 -- Juno Therapeutics, Inc. (NASDAQ: JUNO) and Celgene Corporation (NASDAQ: CELG), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy... Posted: Tue 20th of December, 2016

Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA

NEW YORK, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced today that the U.S. Food and Drug Administration (FDA) has granted... Posted: Mon 19th of December, 2016

Loxo Oncology TRK Inhibitor Larotrectinib (LOXO-101) Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in ESMO Asia Phase 1 Update

STAMFORD, Conn., Dec. 18, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced updated results... Posted: Sun 18th of December, 2016